AIA PACK PA

Prostate-specific Antigen (psa) For Management Of Prostate Cancers

FDA Premarket Approval P910065 S002

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the addition of the aia 600 ii analyzer instrument to the list of approved analyzers using the aia-pack pa assay.

DeviceAIA PACK PA
Classification NameProstate-specific Antigen (psa) For Management Of Prostate Cancers
Generic NameProstate-specific Antigen (psa) For Management Of Prostate Cancers
ApplicantTOSOH BIOSCIENCE, INC.
Date Received1999-12-16
Decision Date2000-03-03
PMAP910065
SupplementS002
Product CodeLTJ
Advisory CommitteeImmunology
Supplement TypeNormal 180 Day Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address TOSOH BIOSCIENCE, INC. 6000 Shoreline Court suite 101 south San Francisco, CA 94080

Supplemental Filings

Supplement NumberDateSupplement Type
P910065Original Filing
S009 2019-05-20 Special (immediate Track)
S008 2011-03-30 Normal 180 Day Track
S007 2009-04-24 Normal 180 Day Track
S006 2005-06-06 Normal 180 Day Track
S005 2004-04-07 Normal 180 Day Track
S004 2003-06-04 Normal 180 Day Track
S003 2002-01-09 Normal 180 Day Track
S002 1999-12-16 Normal 180 Day Track
S001 1999-03-25 Panel Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.